Caption Management LLC lowered its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) by 50.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,777 shares of the company’s stock after selling 18,223 shares during the quarter. Caption Management LLC owned approximately 0.06% of Viridian Therapeutics worth $206,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Qube Research & Technologies Ltd increased its holdings in Viridian Therapeutics by 95.2% in the 1st quarter. Qube Research & Technologies Ltd now owns 33,187 shares of the company’s stock worth $614,000 after acquiring an additional 16,187 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Viridian Therapeutics by 43.2% in the 1st quarter. JPMorgan Chase & Co. now owns 18,666 shares of the company’s stock worth $345,000 after acquiring an additional 5,633 shares in the last quarter. Citigroup Inc. increased its holdings in Viridian Therapeutics by 89.1% in the 1st quarter. Citigroup Inc. now owns 28,140 shares of the company’s stock worth $520,000 after acquiring an additional 13,256 shares in the last quarter. Bank of Montreal Can purchased a new stake in Viridian Therapeutics in the 1st quarter worth approximately $414,000. Finally, Gyon Technologies Capital Management LP purchased a new stake in Viridian Therapeutics in the 1st quarter worth approximately $225,000.
Insider Activity at Viridian Therapeutics
In related news, General Counsel Lara Meisner sold 8,125 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $22.05, for a total value of $179,156.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.48% of the stock is owned by corporate insiders.
Viridian Therapeutics Price Performance
Viridian Therapeutics (NASDAQ:VRDN – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. Viridian Therapeutics had a negative return on equity of 109.29% and a negative net margin of 6,009.30%. The firm had revenue of $1.20 million for the quarter, compared to analyst estimates of $0.52 million. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -3.55 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
VRDN has been the subject of several analyst reports. B. Riley increased their target price on shares of Viridian Therapeutics from $25.00 to $40.00 in a report on Tuesday, August 16th. Wedbush increased their price objective on shares of Viridian Therapeutics to $43.00 in a report on Thursday, November 17th. Evercore ISI increased their price objective on shares of Viridian Therapeutics from $40.00 to $50.00 in a report on Monday, August 15th. LADENBURG THALM/SH SH increased their price objective on shares of Viridian Therapeutics from $33.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Finally, JMP Securities cut their price objective on shares of Viridian Therapeutics from $47.00 to $46.00 and set a “market outperform” rating for the company in a report on Tuesday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $42.00.
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.
- Get a free copy of the StockNews.com research report on Viridian Therapeutics (VRDN)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.